DRUG INTERACTIONS AND ADVERSE DRUG REACTIONS STUDY OF HIV/AIDS PATIENTS WITH TUBERCULOSIS IN DR. HASAN SADIKIN HOSPITAL BANDUNG
Tuberculosis is a disease that often occurs in patients with HIV/AIDS. Both HIV/AIDS and tuberculosis require combination therapy with many kind of drugs. Using many kind of drugs can lead to drug interactions and unwanted drug effects or adverse drug reactions (ADRs). This study aims to determin...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/45965 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Tuberculosis is a disease that often occurs in patients with HIV/AIDS. Both
HIV/AIDS and tuberculosis require combination therapy with many kind of
drugs. Using many kind of drugs can lead to drug interactions and unwanted drug
effects or adverse drug reactions (ADRs). This study aims to determine the
potential of drug interactions in HIV/AIDS patients with tuberculosis, estimation
of ADRs occured, and also treatment recommendations for HIV/AIDS patients
with tuberculosis. This research is a descriptive study which has done
retrospectively in HIV/AIDS patients with tuberculosis who began the treatment
in the Teratai clinic, Dr. Hasan Sadikin Bandung Hospital in 2013. This study
obtains 48 patients that fit the inclusion criteria, namely adult patients, receiving
treatment for tuberculosis in Teratai clinic, Dr. Hasan Sadikin Bandung Hospital
in 2013, and has been receiving treatment for tuberculosis and antiretroviral
therapy. Based on those patients, there were 109 incidences of potential drug
interactions with major significance, 299 incidences of potential drug interactions
with moderate significance, and 58 the incidences of potential drug interactions
with minor significance. Estimated ADRs with the greatest number found in this
study was 8 incidences of gastrointestinal disorders, 5 incidences of drug eruption,
5 drug-induced liver injury (DILI) incidences, and 4 peripheral neuropathy
incidences. Patients receiving tuberculosis therapy category 1 was recommended
to use tenofovir, lamivudine, and efavirenz as antiretroviral therapy, whereas
patients receiving tuberculosis therapy category 2 was recommended to use
zidovudine, lamivudine, and efavirenz as antiretroviral therapy. Based on this
study, there were many potential drug interactions and estimated ADRs on
HIV/AIDS patients with tuberculosis. To manage those effects, we can choose
other drugs that interact minimally or provide other medications to prevent drug
interactions and ADRs.
|
|---|